当前位置： SCI文献检索 > BREAST CANCER RESEARCH AND TREATMENT期刊下所有文献 > Breast cancer and timing of surgery during menstrual cycle: a 5-year analysis of 248 premenopausal women.

Breast cancer and timing of surgery during menstrual cycle: a 5-year analysis of 248 premenopausal women.

Abstract：

:In the present report, we retrospectively analyzed the impact of the timing of surgery during menstrual cycle on disease-free and overall survival of 248 premenopausal patients with stage I/II breast cancer who underwent surgery followed by anthracycline-containing adjuvant chemotherapy. With a median follow-up of 5 years, no statistically significant differences were observed in disease-free or overall survival between women operated upon during the follicular (days 0-14) and the luteal (days 15-32) phase of the menstrual cycle. The impact on disease-free and overall survival of lymph-node status, tumor size and hormone receptor expression, but not of the phase of the menstrual cycle at the time of surgery, was confirmed by univariate and multivariate analysis. However, when combined with hormone receptor status, the phase of the menstrual cycle at the time of surgery proved useful to better define the prognosis of primary breast cancer patients, with significantly longer disease-free and overall survival for patients operated upon during the follicular phase and with positive hormone receptors.

journal_name

Breast Cancer Res Treat

journal_title

Breast cancer research and treatment

authors

Milella M,Nisticò C,Ferraresi V,Vaccaro A,Fabi A,D'Ottavio AM,Botti C,Giannarelli D,Lopez M,Cortesi E,Foggi CM,Antimi M,Terzoli E,Cognetti F,Papaldo P

doi

10.1023/a:1006276120841

subject

Has Abstract

pub_date

1999-06-01 00:00:00

pages

259-66

issue

3

eissn

0167-6806

issn

1573-7217

journal_volume

55

pub_type

临床试验,杂志文章,多中心研究,随机对照试验

相关文献

BREAST CANCER RESEARCH AND TREATMENT文献大全
  • Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer.

    abstract：:Eribulin mesylate, a novel non-taxane microtubule dynamics inhibitor, is approved for treatment of metastatic breast cancer (MBC) in patients who have previously received at least 2 chemotherapeutic regimens for MBC that should have included an anthracycline and a taxane in the adjuvant or metastatic setting. This pha...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,多中心研究

    doi：10.1007/s10549-014-2923-9

    authors： McIntyre K,O'Shaughnessy J,Schwartzberg L,Glück S,Berrak E,Song JX,Cox D,Vahdat LT

    更新日期：2014-07-01 00:00:00

  • Effect of multiplicity, laterality, and age at onset of breast cancer on familial risk of breast cancer: a nationwide prospective cohort study.

    abstract：:The objective of this nationwide prospective cohort study is to find out the risk of breast cancer (BC) in relatives of patients with multiple BCs by laterality and age at diagnosis of first BC. Having family history of single (HR 1.8; 95 % CI 1.8-1.9) or multiple (HR 2.7; 95 % CI 2.6-2.9) BC was associated with highe...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-014-2848-3

    authors： Kharazmi E,Chen T,Narod S,Sundquist K,Hemminki K

    更新日期：2014-02-01 00:00:00

  • Impact of self-reported data on the acquisition of multi-generational family history and lifestyle factors among women seen in a high-risk breast screening program: a focus on modifiable risk factors and genetic referral.

    abstract：BACKGROUND:The phrase "high-risk for breast cancer" is used to identify various groups at elevated cancer risk, and the appropriate surveillance and risk-reducing strategies differ based on the etiology of risk. Here, we review the utility of patient-reported data to capture women with modifiable lifestyle risk factors...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-017-4115-x

    authors： Rosenberger LH,Weber R,Sjoberg D,Vickers AJ,Mangino DA,Morrow M,Pilewskie ML

    更新日期：2017-04-01 00:00:00

  • International multicenter tool to predict the risk of four or more tumor-positive axillary lymph nodes in breast cancer patients with sentinel node macrometastases.

    abstract：:Recently, many centers have omitted routine axillary lymph node dissection (ALND) after metastatic sentinel node biopsy in breast cancer due to a growing body of literature. However, existing guidelines of adjuvant treatment planning are strongly based on axillary nodal stage. In this study, we aim to develop a novel ...

    journal_title：Breast cancer research and treatment

    pub_type： 临床试验,杂志文章,多中心研究

    doi：10.1007/s10549-013-2468-3

    authors： Meretoja TJ,Audisio RA,Heikkilä PS,Bori R,Sejben I,Regitnig P,Luschin-Ebengreuth G,Zgajnar J,Perhavec A,Gazic B,Lázár G,Takács T,Kővári B,Saidan ZA,Nadeem RM,Castellano I,Sapino A,Bianchi S,Vezzosi V,Barranger E,L

    更新日期：2013-04-01 00:00:00

  • Transforming growth factor-beta in breast cancer: a working hypothesis.

    abstract：:Transforming Growth Factor-beta (TGF beta) is the most potent known inhibitor of the progression of normal mammary epithelial cells through the cell cycle. During the early stages of breast cancer development, the transformed epithelial cells appear to still be sensitive to TGF beta-mediated growth arrest, and TGF bet...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,评审

    doi：10.1023/a:1005865812918

    authors： Reiss M,Barcellos-Hoff MH

    更新日期：1997-08-01 00:00:00

  • Mutations in PIK3CA sensitize breast cancer cells to physiologic levels of aspirin.

    abstract：:A review of the literature finds that women diagnosed with breast cancer, who were on an aspirin regimen, experienced a decreased risk of distant metastases and death. Several recent studies have reported an improvement in overall survival in colorectal cancer patients who harbored mutations in the oncogene PIK3CA and...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-016-3729-8

    authors： Turturro SB,Najor MS,Ruby CE,Cobleigh MA,Abukhdeir AM

    更新日期：2016-02-01 00:00:00

  • Targeting trastuzumab-resistant breast cancer cells with a lentivirus engineered to bind antibodies that recognize HER-2.

    abstract：:Targeting HER-2 over-expressing breast cancer cells with trastuzumab has resulted in significant improvements in both disease-free and overall survival rates. However, despite a favorable initial response, some cancer cells become resistant and develop into fatal metastatic disease. Here we report that we can specific...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-010-0828-9

    authors： Zhang KX,Kim C,Chow E,Chen IS,Jia W,Rennie PS

    更新日期：2011-01-01 00:00:00

  • Strategies for the development of recombinant vaccines for the immunotherapy of breast cancer.

    abstract：:The development of recombinant vaccines for specific immunotherapy of carcinoma represents a novel approach for the treatment of breast cancer and other tumor types. This article reviews the various parameters that should be considered in the development of recombinant vaccines. Several breast cancer associated antige...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,评审

    doi：10.1007/BF01803781

    authors： Schlom J,Kantor J,Abrams S,Tsang KY,Panicali D,Hamilton JM

    更新日期：1996-01-01 00:00:00

  • Controlled release low dose medroxyprogesterone acetate (MPA) inhibits the development of mammary tumors induced by dimethyl-benz(a) anthracene in the rat.

    abstract：:Medroxyprogesterone acetate (MPA) is well recognized to have beneficial effects for the treatment of advanced breast cancer which are comparable to those achieved with other forms of endocrine therapy. Using mammary tumors induced in the rat by dimethylbenz(a)anthracene (DMBA) as a model, we have studied the possibili...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/BF00665803

    authors： Labrie F,Li S,Bélanger A,Côté J,Mérand Y,Lepage M

    更新日期：1993-01-01 00:00:00

  • Prevalence of BRCA1 and BRCA2 mutations in breast cancer patients from Brazil.

    abstract：:The contribution of BRCA1 and BRCA2 to breast cancer incidence in Brazil has not yet been explored. In order to estimate the proportion of breast cancers due to BRCA1 and BRCA2 mutations in Brazil, we conducted a study of unselected breast cancer patients from Rio de Janeiro, Brazil. We enrolled 402 women with breast ...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-006-9378-6

    authors： Gomes MC,Costa MM,Borojevic R,Monteiro AN,Vieira R,Koifman S,Koifman RJ,Li S,Royer R,Zhang S,Narod SA

    更新日期：2007-07-01 00:00:00

  • Prospective assessment of the prognostic value of circulating tumor cells and their clusters in patients with advanced-stage breast cancer.

    abstract：:The enumeration of circulating tumor cells (CTCs) provides important prognostic values in patients with metastatic breast cancer. Recent studies indicate that individual CTCs form clusters and these CTC-clusters play an important role in tumor metastasis. We aimed to assess whether quantification of CTC-clusters provi...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-015-3636-4

    authors： Mu Z,Wang C,Ye Z,Austin L,Civan J,Hyslop T,Palazzo JP,Jaslow R,Li B,Myers RE,Jiang J,Xing J,Yang H,Cristofanilli M

    更新日期：2015-12-01 00:00:00

  • Cure of metastatic growth of EMT6 tumor cells in mice following manipulation of CD200:CD200R signaling.

    abstract：:In previous studies, we observed that regulation of expression of CD200, both on cells of a transplantable breast cancer, EMT6, and of the host, as well as of the receptor, CD200R in host mice, regulated local tumor growth and metastasis in immunocompetent animals. This in turn led to an improved ability to document i...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-013-2735-3

    authors： Gorczynski RM,Chen Z,Khatri I,Podnos A,Yu K

    更新日期：2013-11-01 00:00:00

  • EMSY and CCND1 amplification in familial breast cancer: from the Ontario site of the Breast Cancer Family Registry.

    abstract：:EMSY is a putative oncogene amplified in a minority of breast carcinomas, its protein product interacts with and transcriptionally silences BRCA2. We hypothesized that breast tumors from BRCA2 mutation carriers would be less likely than other familial breast cancers to exhibit EMSY amplification. As EMSY is located on...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-011-1380-y

    authors： Bane AL,Mulligan AM,Pinnaduwage D,O'Malley FP,Andrulis IL

    更新日期：2011-06-01 00:00:00

  • (-)-Epigallocatechin (EGC) of green tea induces apoptosis of human breast cancer cells but not of their normal counterparts.

    abstract：:(-)-Epigallocatechin (EGC), one of green tea polyphenols, has been shown to inhibit growth of cancer cells. However its mechanism of action is poorly known. We show here that EGC strongly inhibited the growth of breast cancer cell lines (MCF-7 and MDA-MB-231) but not that of normal breast epithelial cells. The inhibit...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1023/a:1020833410523

    authors： Vergote D,Cren-Olivé C,Chopin V,Toillon RA,Rolando C,Hondermarck H,Le Bourhis X

    更新日期：2002-12-01 00:00:00

  • Loss of heterozygosity at BRCA2 in a ductal carcinoma in situ and three invasive breast carcinomas in a family with a germline BRCA2 mutation.

    abstract：:We have examined a family with a germline BRCA2 mutation in three cases of invasive breast cancer and one case of ductal carcinoma in situ (DCIS). Loss of heterozygosity (LOH) has been demonstrated at the BRCA2 locus in all cases. This result may suggest that the germline mutation in BRCA2 is the initiating step of DC...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-004-9503-3

    authors： Thomassen M,Kruse TA,Olsen KE,Borg A,Gerdes AM

    更新日期：2004-10-01 00:00:00

  • Thyroid hormone receptor α in breast cancer: prognostic and therapeutic implications.

    abstract：:We determined the expression of two transcriptional variants of thyroid hormone receptor alpha (THRα1 and THRα2) in samples from a cohort of breast cancer patients and correlated expression levels with survival. 130 women who were diagnosed with invasive breast carcinoma between 2007 and 2008 were included. Representa...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-014-3235-9

    authors： Jerzak KJ,Cockburn J,Pond GR,Pritchard KI,Narod SA,Dhesy-Thind SK,Bane A

    更新日期：2015-01-01 00:00:00

  • Tamoxifen metabolism is altered by simultaneous administration of medroxyprogesterone acetate in breast cancer patients.

    abstract：:We have measured the levels of tamoxifen and three of its metabolites in the blood of patients receiving tamoxifen alone or combination therapy with tamoxifen and medroxyprogesterone acetate. Our results indicate that addition of the progestogen significantly alters the metabolism of tamoxifen over a six-month period....

    journal_title：Breast cancer research and treatment

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1007/BF01833345

    authors： Reid AD,Horobin JM,Newman EL,Preece PE

    更新日期：1992-01-01 00:00:00

  • Short and long-term effects on survival in breast cancer patients treated by primary chemotherapy: an updated analysis of a randomized trial.

    abstract：:A potential advantage of primary over adjuvant chemotherapy in breast cancer survival had been proposed on theoretical grounds. In 1994, early results of the S6-trial comparing primary chemotherapy vs. adjuvant chemotherapy for operable breast cancer in 390 premenopausal patients had shown significant improvement in s...

    journal_title：Breast cancer research and treatment

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1023/a:1006339918798

    authors： Broët P,Scholl SM,de la Rochefordière A,Fourquet A,Moreau T,De Rycke Y,Asselain B,Pouillart P

    更新日期：1999-11-01 00:00:00

  • ErbB-2 protein in sera and tumors of breast cancer patients.

    abstract：:We compared levels of erbB-2 oncoprotein among three groups: Group I included 60 asymptomatic women; Group II had 51 women with benign breast biopsies; and Group III had 67 women with node-negative breast cancer. Serological levels of erbB-2 protein were measured in all participants; tumor levels were measured for Gro...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1023/a:1006033214721

    authors： Breuer B,Smith S,Thor A,Edgerton S,Osborne MP,Minick R,Cody HS 3rd,Nowak E,Cortese A,Simmons RM,Carney WP,Brandt-Rauf PW

    更新日期：1998-06-01 00:00:00

  • Multiple growth factor independence in rat mammary carcinoma cells.

    abstract：:In previous studies we demonstrated that rat mammary tumor (RMT) cells that are serially transplantable consist of cells that are independent of growth factors strictly required by normal rat mammary epithelial (RME) cells for growth in serum-free culture. The present studies were designed to determine the extent of t...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/BF01980969

    authors： Ethier SP,Moorthy R

    更新日期：1991-05-01 00:00:00

  • Adoptively transferred ex vivo expanded gammadelta-T cells mediate in vivo antitumor activity in preclinical mouse models of breast cancer.

    abstract：:In contrast to antigen-specific alphabeta-T cells (adaptive immune system), gammadelta-T cells can recognize and lyse malignantly transformed cells almost immediately upon encounter in a manner that does not require the recognition of tumor-specific antigens (innate immune system). Given the well-documented capacity o...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-009-0527-6

    authors： Beck BH,Kim HG,Kim H,Samuel S,Liu Z,Shrestha R,Haines H,Zinn K,Lopez RD

    更新日期：2010-07-01 00:00:00

  • Old masters as clinical photographers: multifocal breast cancer diagnosed 400 years ago.

    abstract：:It is common belief among physicians the idea that breast cancer was not diagnosed centuries ago. Nevertheless, there are reports suggesting that old masters and even common people knew this dramatic disease. In the 16th and 17th centuries, famous artists painted things exactly as they saw them. This allows the detect...

    journal_title：Breast cancer research and treatment

    pub_type： 历史文章,杂志文章

    doi：10.1007/s10549-007-9753-y

    authors： Grau JJ,Estrach T

    更新日期：2008-09-01 00:00:00

  • What is the biological, prognostic, and therapeutic role of the EGF receptor in human breast cancer?

    abstract：:The epidermal growth factor receptor (EGFR) is expressed in benign and malignant breast epithelium. The EGFR, when mutated or over-expressed in the presence of its ligand, is transforming in other tissues or cell types. It is therefore of major interest in the pathogenesis of human breast cancer to understand the role...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/BF00666176

    authors： Harris AL

    更新日期：1994-01-01 00:00:00

  • Mismatch repair defective breast cancer in the hereditary nonpolyposis colorectal cancer syndrome.

    abstract：:Whether or not breast cancer can be a feature of the hereditary nonpolyposis colorectal cancer (HNPCC) syndrome has been debated. In order to clarify if defective mismatch repair (MMR) may indeed play a role in breast cancer, we used the Danish HNPCC register to identify all breast cancers that occurred in MMR gene mu...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-009-0449-3

    authors： Jensen UB,Sunde L,Timshel S,Halvarsson B,Nissen A,Bernstein I,Nilbert M

    更新日期：2010-04-01 00:00:00

  • High risk of breast cancer in women with biallelic pathogenic variants in CHEK2.

    abstract：PURPOSE:Compared to breast cancer risk genes such as BRCA2, ATM, PALB2, and NBN, no defined phenotype is currently associated with biallelic pathogenic variants (PVs) in CHEK2. This study compared the prevalence of breast and other cancers in women with monoallelic and biallelic CHEK2 PVs. METHODS:CHEK2 PV carriers we...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-020-05543-3

    authors： Rainville I,Hatcher S,Rosenthal E,Larson K,Bernhisel R,Meek S,Gorringe H,Mundt E,Manley S

    更新日期：2020-04-01 00:00:00

  • Preclinical evaluation of nuclear morphometry and tissue topology for breast carcinoma detection and margin assessment.

    abstract：:Prevention and early detection of breast cancer are the major prophylactic measures taken to reduce the breast cancer related mortality and morbidity. Clinical management of breast cancer largely relies on the efficacy of the breast-conserving surgeries and the subsequent radiation therapy. A key problem that limits t...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-010-0914-z

    authors： Nyirenda N,Farkas DL,Ramanujan VK

    更新日期：2011-04-01 00:00:00

  • The effect of age and density of the breast on the sensitivity of breast cancer diagnostic by mammography and ultasonography.

    abstract：PURPOSE:We studied which, age of the patient or density of the breast accounts for the sensitivity of mammography and ultrasonography (US). Furthermore we studied whether the overall impression on the density of the breast or the density in tumour area accounts for the sensitivity of mammography and ultrasonography. M...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1023/a:1010627527026

    authors： Saarenmaa I,Salminen T,Geiger U,Heikkinen P,Hyvärinen S,Isola J,Kataja V,Kokko ML,Kokko R,Kumpulainen E,Kärkkäinen A,Pakkanen J,Peltonen P,Piironen A,Salo A,Talviala ML,Haka M

    更新日期：2001-05-01 00:00:00

  • Factors associated with long-term adherence to annual surveillance mammography among breast cancer survivors.

    abstract：:Clinical practice guidelines recommend yearly surveillance mammography for breast cancer survivors, yet many women do not receive this service. The objective of this study was to evaluate factors related to long-term surveillance mammography adherence among breast cancer survivors. We conducted a retrospective cohort ...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-013-2816-3

    authors： Wirtz HS,Boudreau DM,Gralow JR,Barlow WE,Gray S,Bowles EJ,Buist DS

    更新日期：2014-02-01 00:00:00

  • Effects of exercise intervention in breast cancer patients: is mobile health (mHealth) with pedometer more effective than conventional program using brochure?

    abstract：PURPOSE:To investigate and compare the effects of mobile health (mHealth) and pedometer with conventional exercise program using a brochure on physical function and quality of life (QOL). METHODS:The study was a prospective, quasi-randomized multicenter trial where 356 patients whose cancer treatment had been terminat...

    journal_title：Breast cancer research and treatment

    pub_type： 临床试验,杂志文章,多中心研究,随机对照试验

    doi：10.1007/s10549-016-4065-8

    authors： Uhm KE,Yoo JS,Chung SH,Lee JD,Lee I,Kim JI,Lee SK,Nam SJ,Park YH,Lee JY,Hwang JH

    更新日期：2017-02-01 00:00:00

  • Patient-reported outcome after oncoplastic breast surgery compared with conventional breast-conserving surgery in breast cancer.

    abstract：INTRODUCTION:Oncoplastic breast surgery (OBS) has developed as an extension of breast-conserving surgery (BCS) in an effort to improve esthetic and functional outcome following surgery for breast cancer. The aim of the present study was to evaluate the possible benefits of OBS, as compared with BCS, with regard to heal...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-020-05544-2

    authors： Rose M,Svensson H,Handler J,Hoyer U,Ringberg A,Manjer J

    更新日期：2020-02-01 00:00:00